February 18, 2022
This phase III study demonstrates that the combination of paclitaxel and carboplatin is non-inferior to the combination of paclitaxel and ifosfamide for the treatment of patients […]
February 18, 2022
Phase III data from the 309- KEYNOTE-775 study demonstrate that the combination of levantinib plus pembrolizumab was beneficial for patients with advanced endometrial cancer who had […]
February 18, 2022
Clinical trial EMPOWER-Cervical 1 demonstrates an overall survival benefit of using cemiplimab as monotherapy, compared with chemotherapy of investigator’s choice, for patients with recurrent or metastatic […]
October 21, 2020
Study results BLC2001 (757P – An observational study of outcomes of patients (pts) with advanced urothelial carcinoma (UC) after anti-programmed death- (Ligand) 1 (PD- [L] 1) […]
October 20, 2020
The efficacy of olaparib as maintenance therapy in newly diagnosed advanced ovarian cancer with BRCA mutation: 5-year follow-up from SOLO-1 trial Patients with newly diagnosed advanced […]
May 27, 2020
Results of the CheckMate 227 trial demonstrate gains in overall survival with the dual immunotherapy approach with nivolumab and ipilimumab The US Food and Drug Administration […]
May 15, 2020
Pivotal phase III trial included approximately 600 patients not eligible for curative surgery Nivolumab in combination with ipilimumab demonstrated statistically and clinically significant gains of overall […]
May 13, 2020
Fast Track is based on the response rate and duration of the response and reinforces the premise that the Trop-2 antigen is an important target to […]
May 6, 2020
The results were presented in the “Clinical Plenary: Lung Cancer Targeted Therapy” session of AACR 2020 Phase 2 study presented during the AACR Annual Meeting 2020 […]